Innovative Therapeutics in Oncology and Neuroscience
3
Building a Global Pipeline through Internal Discovery Efforts and...
Focused Discovery Efforts
ଢ Oncology
Oncogenic Driver Mutations
DNA Damage Repair &
Synthetic Lethality
TAA / TME targeted ADC / bispecific
.
Phase 1
ZL-1310 (DLL3 ADC)
• A next generation ADC platform
· Topoisomerase 1 inhibitor payload with high potency, high clearance and better
permeability
.
ZL-1218 (CCR8)
Phase 1
• A novel antibody targeting CCR8 receptors that are selectively expressed on
Tregs in solid tumors
.
Demonstrated an encouraging pre-clinical profile
(8
Immunology
VHH Antibody
•
ZL-1102 (IL-17 HumabodyⓇ)
High affinity human Vч fragment antibody targeting IL-17A
H
Entering Phase 2
• First-ever to demonstrate penetration of protein biologic through psoriatic skin
resulting in clinical response¹
Aiming to Generate at Least One Global IND per Year
Abbreviations: Variable domain of heavy chain of heavy chain antibody (VHH), tumor-associated antigen (TAA), regulatory T cells (Tregs), tumor microenvironment (TME), antibody-drug conjugate (ADC), investigation new drug (IND).
Note: (1) Topical application of a novel anti-interleukin-17A antibody fragment penetrates psoriatic skin: Results of a randomized, double-blind, placebo-controlled Phase Ib study, 2023.
zaiLab
13View entire presentation